PT  - JOURNAL ARTICLE
AU  - Parry, Nicola
ED  - Cappato, Riccardo
TI  - X-VeRT Results: Rivaroxaban is Safe and Effective for Cardioversion in AF
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 27--27
VI  - 14
IP  - 27
4099  - http://mdc.sagepub.com/content/14/27/27.1.short
4100  - http://mdc.sagepub.com/content/14/27/27.1.full
AB  - This article presents results from the Explore the Efficacy and Safety of Once-Daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion trial [X-VeRT; Cappato R et al. Eur Heart J. 2014]. The data showed that oral rivaroxaban was as effective and safe as a vitamin K antagonist when administered for only about a week prior to elective cardioversion for atrial fibrillation.